ANTIMANIA DRUGS MARKET ANALYSIS(2020-2027)

1

• Coherent Market Insights
• Market Research and Business Consulting Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
ANTIMANIA DRUGS MARKET ANALYSIS (2020-2027)

• Antimania Drugs Market, by Drug (Lithium Salts,
  Carbamazepine, Valproic Acid, Lamotrigine,
  Olanzapine, and Others), by Distribution Channel
  (Hospital Pharmacies, Retail Pharmacies, and
  Online Pharmacies), and by Region (North America,
  Latin America, Europe, Middle East, Asia Pacific,
  and Africa) - Size, Share, Outlook, and
  Opportunity Analysis, 2020 - 2027

3

• Antimania drugs are used in the treatment of
  bipolar disorder, a type of mood disorder also
  called as manic depression or manic-depressive
  illness, where patients mood fluctuate from
  feeling depressed to feeling super charged or
  manic.
• The most widely used medication for the treatment
  of acute mania include lithium, valproate
  carbamazepine (antipsychotics), ziprasidone,
  aripiprazole clozapine (atypical
  antipsychotics), and lorazepam (benzodiazepine).
  Additionally, for the treatment of prophylaxis of
  bipolar mood disorder, lithium carbonate and
  lithium citrate are mostly used. Carbamazepine
  reduces transmission of the nerve impulse in the
  brain, which in turn reduces severity of manic
  episodes. Moreover, carbamazepine can be used as
  alternative to lithium salts, when patients fails
  to respond to lithium. Furthermore, sometimes
  carbamazepine are used with the combination of
  lithium, when there is need of rapid control of
  acute mania.

4

• Global Antimania Drugs Market Drivers  
• The global antimania drugs market is expected to
  witness significant growth over the forecast
  period, owing to growing prevalence of bipolar
  disorder, globally. For instance, according to
  the World Health Organization (WHO) 2019 report,
  around 45 million people get affected by bipolar
  disorder globally.
• Moreover, cost effectiveness of drugs for the
  treatment of bipolar disorder is another factor
  that is expected to drive the global antimania
  drugs market growth over the forecast period. For
  instance, cost of olanzapine is US 153, while
  cost of lithium is US 16 per month.

5

• Furthermore, increasing number of clinical trials
  of drug for the treatment of bipolar depression,
  which is expected to propel the global antimania
  drugs market growth over the forecast period. For
  instance, in July 2018, Lumateperone received
  positive results from the Phase 3 clinical trial
  (Study 401 and Study 404) for the treatment of
  bipolar depression, announced by Intra-Cellular
  Therapies, Inc. In both the trials (Study 401 and
  Study 404), Lumateperone was found safer and
  tolerable by patients.
• Moreover, in October 2019, Psychiatry Consortium,
  which is a strategic collaboration of leading
  medical research charities and pharmaceutical
  companies to accelerate innovative drug discovery
  in psychiatric diseases, had announced to launch
  a novel drug project to address people with
  mental health conditions such as bipolar
  disorder, depression and other mental disorders.

6

• Psychiatry Consortium is a pioneering
  collaboration between the pharmaceutical
  companies, healthcare companies as well as
  leading medical charities. Therefore, increasing
  initiatives by companies to support the novel
  drug project, which in turn, is expected to
  increase the launch of new drugs for treatment of
  patients with mental health condition such as
  bipolar disorder and hence drives the global
  antimania drugs market growth.

7

• Global Antimania Drugs Market Restraints
• However, side effects associated with lithium for
  the treatment of bipolar disorder is one of the
  major factors that is expected to restrain the
  global antimania drugs market growth over the
  forecast period. For instance, if patient takes
  overdose of lithium, it causes anorexia. 
  Moreover, prolong use of lithium can damage
  bodys ability to respond properly to
  the hormone vasopressin and can result into
  diabetes insipidus.

8

• Global Antimania Drugs Market Regional Analysis
• North America is expected to hold the highest
  market share in global antimania drugs market,
  owing to factors such as increasing technological
  advancements such as BiAffect app by  University
  of Illinois, Chicago that helps to facilitate
  accurate detection of a patients mood and mental
  state. For instance, in 2018, the University of
  Illinois, Chicago (UIC) launched BiAffect app,
  which helps to track manic disorder and
  depressive mood in the patient with biopolar
  disorder. Moreover, BiAffect app predict mood
  episodes by analyzing the stroke dynamics such as
  error and typing speed of the patient. Therefore,
  launch of BiAffect app is expected to drive
  demand of antimania drugs for the treatment of
  bipolar disorder.

9

• Moreover, increasing approvals of drug such as
  Vraylar by U.S Food and Drug administration (FDA)
  for the treatment of bipolar disorder is another
  factor that is expected to boost global antimania
  drugs market growth. For instance, in May 2019,
  Allergan plc and Gedeon Richter Plc announced to
  receive the approval from the U.S Food Drug
  Administration for expanded use of
  Vraylar (cariprazine) in the treatment of
  depressive episodes associated with bipolar I
  disorder (bipolar depression) in adults.
• Among regions, Europe is expected to hold the
  second highest market share in global antimania
  drug market, owing to increasing launches of new
  drugs for the treatment of bipolar disorder in
  Europe. For instance, in September 2019, LATUDA,
  an atypical antipsychotic agent was launched by
  Sumitomo Dainippon Pharma Co., Ltd., in China.
  LATUDA is used for the treatment bipolar
  depression. Additionally, the National Medical
  Products Administration (NMPA) has granted import
  drug license for LATUDA drug in China.

10

• Global Antimania Drugs Market Key Players
• Key players operating in the global antimania
  market are Eli Lilly and Company, Sumitomo
  Dainippon Pharma Co., Ltd, Allergan plc, Xian
  Janssen Pharmaceutical Ltd, Pfizer Inc., Otsuka
  Pharmaceutical, Taro Pharmaceutical Industries
  Ltd, Apotex Inc., Teva Pharmaceutical Industries
  Ltd, and Torrent Pharmaceutical Ltd.

11

• Market Taxonomy
• On the basis of drug, the global antimania drugs
  market is segmented into
• Lithium Salts
• Carbamazepine
• Valproic Acid
• Lamotrigine
• Olanzapine
• Others

12

• On the basis of distribution channel, the global
  antimania drugs market is segmented into
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• On the basis of region, the global antimania
  drugs market is segmented into
• North America
• Latin America
• Europe
• Middle East
• Asia Pacific
• Africa

13

• Request Sample Report
• Request Customization
• Download PDF Brochure
• Talk to Analyst
• Buy Now
• Reference https//www.coherentmarketinsights.com/
  ongoing-insight/antimania-drugs-market-4143

14
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

15
Contact Us

• Mr. Shah
• Coherent Market Insights Pvt.Ltd.
• Address 1001 4th Ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

16

• Thank You!
• Kindly follow CMI Social Media
  Profiles for the latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/